Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury

Journal of Neurosurgery

Volumn 106, Issue 4, 2007, Pages 538-547

  Wagner, Amy K ^a,b,c   Ren, Dianxu ^c   Conley, Yvette P ^a,c   Ma, Xiecheng ^a,b   Kerr, Mary E ^d   Zafonte, Ross D ^a   Puccio, Ava M ^a   Marion, Donald W ^e   Dixon, C Edward ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e Brain Trauma Foundation   (United States)

Author keywords

Cerebrospinal fluid; Dihydroxyphenylacetic acid; Dopamine; Genetic polymorphism; Homovanillic acid; Sex based difference; Traumatic brain injury

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METABOLISM; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE UPTAKE; FEMALE; GENETIC ASSOCIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INJURY SEVERITY; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; TRAUMATIC BRAIN INJURY;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; BRAIN INJURIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENOTYPE; GLASGOW COMA SCALE; HOMOVANILLIC ACID; HUMANS; MALE; SEX FACTORS; TIME FACTORS;

EID: 34047194688     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2007.106.4.538     Document Type: Article

References (59)

1. Agnati LF, Bjelke B, Fuxe K: Volume versus wiring transmission in the brain: a new theoretical frame for neuropsychopharmacology. Med Res Rev 15:33-45, 1995
2. Beaumont A, Hayasaki K, Marmarou A, Barzo P, Fatouros P, Corwin F: Contrasting effects of dopamine therapy in experimental brain injury. J Neurotrauma 18:1359-1372, 2001
3. Becker JB: Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 64:803-812, 1999
4. Borland LM, Michael AC: Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem 91:220-229, 2004
5. Bullock R, Chesnut RM, Clifton G, Ghajar J, Marion DW, Narayan RK, et al: Guidelines for the management of severe head injury. Brain Trauma Foundation. Eur J Emerg Med 3:109-127, 1996
6. Clifton GL, Miller ER, Choi SC, Levin HS, McCauley S, Smith KR Jr, et al: Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 344:556-563, 2001
7. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, et al: Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998, 1995
8. Daws LC, Callaghan PD, Moron JA, Kahlig KM, Shippenberg TS, Javitch JA, et al: Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290:1545-1550, 2002
9. Dixon CE, Kraus MF, Kline AE, Ma X, Yan HQ, Griffith RG, et al: Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restor Neurol Neurosci 14:285-294, 1999
10. Dluzen DE: Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 29:387-399, 2000
11. Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, et al: Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med 27:1410-1414, 2000
12. Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI: Population genetic study of the human dopamine transporter gene (DAT1). Genet Epidemiol 12:303-308, 1995
13. Engelborghs S, Marescau B, De Deyn PP: Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem Res 28:1145-1150, 2003
14. Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, et al: Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy postmenopausal women. Am J Geriatr Psychiatry 12:621-630, 2004
15. Garris PA, Ciolkowski EL, Pastore P, Wightman RM: Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14:6084-6093, 1994
16. 3H] noradrenaline in rat hippocampal slices. Neuroscience 104: 761-768, 2001
17. Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, et al: The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. J Neural Transm 108:189-204, 2001
18. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612, 1996
19. Gulley JM, Zahniser NR: Rapid regulation of dopamine transporter function by substrates, blockers, and presynaptic receptor ligands. Eur J Pharmacol 479:139-152, 2003
20. Hastings TG, Lewis DA, Zigmond MJ: Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 387:97-106, 1996
21. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, et al: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133-139, 2000
22. Horn AS: Dopamine uptake: a review of progress in the last decade. Prog Neurobiol 34:387-400, 1990
23. Jiang H, Xie T, Ramsden DB, Ho SL: Human catechol-O- methyltransferase down-regulation by estradiol. Neuropharmacology 45:1011-1018, 2003
24. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Carom MG: Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 95: 4029-4034, 1998
25. Jonsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC: A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 34:239-244, 2000
26. Kelly SJ, Ostrowski NL, Wilson MA: Gender differences in brain and behavior: hormonal and neural bases. Pharmacol Biochem Behav 64:655-664, 1999
27. Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A: Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na1-dependant mechanism. J Biol Chem 278: 12070-12077, 2003
28. Kline AE, Massucci JL, Marion DW, Dixon CE: Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. J Neurotrauma 19:415-425, 2002
29. Kline AE, Yan HQ, Bao J, Marion DW, Dixon CE: Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. Neurosci Lett 280:163-166, 2000
30. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285:107-110, 2000
31. Kroppenstedt SN, Stover JF, Unterberg AW: Effects of dopamine on posttraumatic cerebral blood flow, brain edema, and cerebrospinal fluid glutamate and hypoxanthine concentrations. Crit Care Med 28:3792-3798, 2000
32. Lambert G, Naredi S, Eden E, Rydenhag B, Friberg P: Monoamine metabolism and sympathetic nervous activation following subarachnoid haemorrhage: influence of gender and hydrocephalus. Brain Res Bull 58:77-82, 2002
33. Laranjinha J, Cadenas E: Oxidation of DOPAC by nitric oxide: effect of superoxide dismutase. J Neurochem 81:892-900, 2002
34. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA: Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27: 867-869, 2000
35. Massucci JL, Kline AE, Ma X, Zafonte RD, Dixon CE: Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett 372: 127-131, 2004
36. McEwen B: Estrogen actions throughout the brain. Recent Prog Horm Res 57:357-384, 2002
37. McIntosh TK, Yu T, Gennarelli TA: Alterations in regional brain catecholamine concentrations after experimental brain injury in the rat. J Neurochem 63:1426-1433, 1994
38. Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP: The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 79:1033-1038, 2001
39. Morissette M, Di Paolo T: Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 58:16-22, 1993
40. Newcorn JH: New treatments and approaches for attention deficit hyperactivity disorder. Curr Psychiatry Rep 3:87-91, 2001
41. Nirenberg MJ, Chan J, Pohorille A, Vaughan RA, Uhl GR, Kuhar MJ, et al: The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci 17:6899-6907, 1997
42. Oechsner M, Buhmann C, Strauss J, Stuerenberg HJ: COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. J Neural Transm 109:69-75, 2002
43. Plenger PM, Dixon CE, Castillo RM, Frankowski RF, Yablon SA, Levin HS: Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 77: 536-540, 1996
44. Porta M, Bareggi SR, Collice M, Assael BM, Selenati A, Calderini G, et al: Homovanillic acid and 5-hydroxyindole-acetic acid in the CSF of patients after a severe head injury. II. Ventricular CSF concentrations in acute brain post-traumatic syndromes. Eur Neurol 13:545-554, 1975
45. Ract C, Vigue B, Bodjarian N, Mazoit JX, Samii K, Tadie M: Comparison of dopamine and norepinephrine after traumatic brain injury and hypoxic-hypotensive insult. J Neurotrauma 18: 1247-1254, 2001
46. Raiteri M, Cerrito F, Cervoni AM, Del Carmine R, Ribera MT, Levi G: Release of dopamine from striatal synaptosomes. Ann Ist Super Sanita 14:97-110, 1978
47. Rivest R, Falardeau P, Di Paolo T: Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692:269-272, 1995
48. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI: Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18:2697-2708, 1998
49. Smith TS, Parker WD Jr, Bennett JP Jr: L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 5:1009-1011, 1994
50. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, et al: Dopamine genes and ADHD. Neurosci Biobehav Rev 24:21-25, 2000
51. Vecht CJ, van Woerkom CA, Teelken AW, Minderhoud JM: Homovanillic acid and 5-hydroxyindoleacetic acid cerebrospinal fluid levels. A study with and without probenecid administration of their relationship to the state of consciousness after head injury. Arch Neurol 32:792-797, 1975
52. Wagner AK, Chen X, Kline AE, Li Y, Zafonte RD, Dixon CE: Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury. Exp Neurol 195:475-483, 2005
53. Wagner AK, Sokoloski JE, Ren D, Chen X, Khan AS, Zafonte RD, et al: Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J Neurochem 95:457-465, 2005
54. Whyte J, Hart T, Schuster K, Fleming M, Polansky M, Coslett HB: Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. Am J Phys Med Rehabil 76:440-450, 1997
55. Xie T, Ho SL, Ramsden D: Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56:31-38, 1999
56. Yan HQ, Kline AE, Ma X, Hooghe-Peters EL, Marion DW, Dixon CE: Tyrosine hydroxylase, but not dopamine beta-hydroxylase, is increased in rat frontal cortex after traumatic brain injury. Neuroreport 12:2323-2327, 2001
57. Yates CM, Tsementzis SA, Wilson H: Amine metabolites in ventricular cerebrospinal fluid in coma. J Neurol Neurosurg Psychiatry 42:887-891, 1979
58. Youdim M, Riederer PF: A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 63 (2 Suppl):S32-S35, 2004
59. Zhang H, Zhai SD, Li YM, Chen LR: Effect of different sample pretreatment methods on the concentrations of excitatory amino acids in cerebrospinal fluid determined by high-performance liquid chromatography. J Chromotogr B Analyt Technol Biomed Life Sci 784:131-135, 2003